In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...

US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration (AMD). Izervay can cause side effects that range from mild to serious. Examples ...

James reiterated its Strong Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS), with a price target of $78.00. The stock, ...

Piper Sandler reaffirmed its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a steady price target of $32.00. The firm's analysis was based on a recent survey of ophthalmologists ...

"We are pleased with the FDA's decision to extend the use of IZERVAY for longer-term administration—further solidifying IZERVAY's status as a trusted choice for thousands of GA patients since ...